Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · IEX Real-Time Price · USD
14.92
+1.71 (12.94%)
At close: Apr 26, 2024, 4:00 PM
15.00
+0.08 (0.54%)
After-hours: Apr 26, 2024, 7:04 PM EDT
DAWN Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
155
Market Cap
1.30B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.20B |
| Brookdale Senior Living | 3.02B |
| Agiliti | 1.17B |
| NovoCure | 509.34M |
| ANI Pharmaceuticals | 486.82M |
| Ironwood Pharmaceuticals | 442.74M |
| Kiniksa Pharmaceuticals | 270.26M |
| Establishment Labs Holdings | 165.15M |
DAWN News
- 3 days ago - Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor - GlobeNewsWire
- 2 months ago - Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress - GlobeNewsWire
- 4 months ago - Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 months ago - Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine - GlobeNewsWire
- 6 months ago - Day One Reports Third Quarter 2023 Financial Results and Corporate Progress - GlobeNewsWire
- 6 months ago - Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) - GlobeNewsWire
- 8 months ago - Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) - GlobeNewsWire
- 9 months ago - Day One Reports Second Quarter 2023 Financial Results and Corporate Progress - GlobeNewsWire